BACK TO CONTENTS   |    PDF   |    PREVIOUS   |    NEXT

Title

 

 

 

 

 

LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma

 

Authors

 

Oluwadayo Oluwadara1, Luca Giacomelli2, Russell Christensen3, George Kossan1, Raisa Avezova1, Francesco Chiappelli1*

 

Affiliation

 

1UCLA School of Dentistry, Division of Oral Biology and Medicine, 10833 Le Conte Avenue CHS - Box 951668, Los Angeles, CA 90095-1668, USA, 2Tirrenian Stomatologic Institute, Lido di Camaiore (Lucca), Italy, 3UCLA Division of Oral and Maxillofacial Pathology, USA

 

Email

 

FChiappelli@dentistry.ucla.edu

Article Type

 

Hypothesis

Date

 

Received November 25, 2009; Accepted December 15, 2009; Published December 31, 2009

 

Abstract

T cell signaling is critical in oral lichen planus (OLP) based on the pathogenesis of this chronic inflammatory autoimmune mucocutaneous lesion. Lck plays a key role in T cell signaling; ultimately this signaling affects other targets such as PI-3K. Excessive activity in PI-3K inhibits apoptosis and promotes uncontrolled cell growth. Molecular biomarker profiling in OLP, Chronic Interface Mucosities (CIM), Epithelial Dysplasia (EpD) and Oral Squamous Cell Carcinoma (SCCA) with application of the principle of biomarker voting may represent a new frontier in the diagnosis, assessment and the arguable debate of OLP transformation to cancer. The presence of Lck, PI-3K and Survivin, a cancer specific anti-apoptotic protein was assessed, using immunohistochemistry and tissue micro-array on patient samples, in OLP, SCCA, CIM and EpD. Lck expression was very high in 78.6 % of OLP patients compared to 3.7% in SCCA; PI-3K was high in 63% of SCCA, 100% of EpD, and 35.7% OLP cases. Survivin was high in 64.3% of OLP cases, 96.3% of SCCA, and 100% of EpD. CIM cases may be slightly different molecularly to OLP. Taken together, our data suggest that biomarker protein voting can be effectively used to isolate high-risk OLP cases.  Specifically, we show data with four remarkable cases demonstrating that molecular factors are predictive of histopathology. We conclude that it is safer to treat OLP as premalignant lesions, to adopt aggressive treatment measure in histopathologic described well and moderately differentiated SCCA, and to monitor progress of these diseases molecularly using individualized auto-proteomic approach.  The use of Lck inhibitors in OLP management needs to be investigated in the future.

 

Keywords

oral carcinoma; biomarker; cancer; cellular immunity

 

Citation

 

Oluwadara et al., Bioinformation 4(6): 248-257 (2009)

Edited by

 

P. Kangueane

 

ISSN

 

0973-2063

 

Publisher

Biomedical Informatics

License

 

 

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.